IP Library Granted Patent US 9,833,002
Granted Patent B2
US 9,833,002 · App. 15/193,983 · Granted Dec 5, 2017

Biocide compositions

Inventors: Victor Keasler (Richmond, TX); Jeffrey Caleb Clark (Sugar Land, TX); Carrie Keller-Schultz (Austin, TX); Brian Bennett (Sugar Land, TX)
Assignee: Ecolab USA Inc.
A01N57/34A01N33/12A01N43/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,833,002
App. No.
15/193,983
Granted
Dec 5, 2017
Kind
B2
Abstract

Disclosed are biocide compositions. The compositions are useful in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed are methods of using the compositions, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas.

Claims (105)

1. A method of controlling microbe proliferation in a system used in a coal-fired process, a waste-water process, a farm, a slaughter house, a land-fill, a municipality waste-water plant, a coking coal process, or a biofuel process, the method comprising contacting the system with an effective amount of a biocide composition, the biocide composition comprising

an imidazoline compound;

a quaternary amine; and

a phosphonium compound;

wherein the imidazoline compound has a structure of formula (I), (II), or (III),

wherein

R 1 , R 4 , and R 5 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle each independently, at each occurrence, unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, —COR 6 , —CO 2 R 7 , —SO 3 R 8 , —PO 3 H 2 ,)—CON(R 9 )(R 10 ), —OR 11 , and —N(R 12 )(R 13 );

R 2 is a radical derived from a fatty acid;

R 3 and R x are independently selected from a radical derived from an unsaturated acid;

R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl;

R 12 and R 13 are each independently, at each occurrence, selected from hydrogen, alkyl, —COR 14 , —CO 2 R 15 , -alkyl-COR 16 , and -alkyl-CO 2 R 17 ; and

R 14 ,R 15 , R 16 , and R 17 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl.

2. The method of claim 1 , wherein the imidazoline compound has formula (I),

wherein

R 1 , R 4 , and R 5 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle each independently, at each occurrence, unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, -COR 6 , —CO 2 R 7 , —SO 3 R 8 , —PO 3 H 2 , —CON(R 9 )(R 10 ) —OR 11 , and —N(R 12 )(R 13 );

R 2 is a radical derived from a fatty acid;

R 3 is selected from a radical derived from an unsaturated acid;

R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl;

R 12 and R 13 are each independently, at each occurrence, selected from hydrogen, alkyl, —COR 14 , —CO 2 R 15 , -alkyl-COR 16 , and -alkyl-CO 2 R 17 ; and

R 14 , R 15 , R 16 , and R 17 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl.

3. The method of claim 2 , wherein

R 1 is unsubstituted C 2 -C 6 -alkyl;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 3 is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R 4 is hydrogen; and

R 5 is hydrogen.

4. The method of claim 2 , wherein

R 1 is linear C 2 -alkyl, substituted with one substituent that is a terminal —N(R 12 )(R 13 ), wherein R 12 is hydrogen and R 13 is —COR 14 , wherein R 14 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 3 is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R 4 is hydrogen; and

R 5 is hydrogen.

5. The method of claim 2 , wherein

R 1 is linear C 2 -alkyl, substituted with one substituent that is a terminal —N(R 12 )(R 13 ), wherein R 12 and R 13 are each a —C 2 -alkyl-CO 2 R 17 , wherein R 17 is hydrogen or R 17 is absent;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 3 is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R 4 is hydrogen; and

R 5 is hydrogen.

6. The method of claim 1 , wherein the imidazoline compound has formula (II),

wherein

R 1 , R 4 , and R 5 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle each independently, at each occurrence, unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, —COR 6 , —CO 2 R 7 , —SO 3 R 8 , —PO 3 H 2 ,)—CON(R 9 )(R 10 ), —OR 11 , and —N(R 12 )(R 13 );

R 2 is a radical derived from a fatty acid;

R 3 and R x are each independently selected from a radical derived from an unsaturated acid;

R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl;

R 12 and R 13 are each independently, at each occurrence, selected from hydrogen, alkyl, —COR 14 , —CO 2 R 15 , -alkyl-COR 16 , and -alkyl-CO 2 R 17 ; and

R 14 , R 15 , R 16 , and R 17 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl.

7. The method of claim 6 , wherein

R 1 is unsubstituted C 2 -C 6 -alkyl;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 3 is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R x is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R 4 is hydrogen; and

R 5 is hydrogen.

8. The method of claim 6 , wherein

R 1 is linear C 2 -alkyl, substituted with one substituent that is a terminal —N(R 12 )(R 13 ), wherein R 12 is hydrogen and R 13 is —COR 14 , wherein R 14 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 2 is —C i7 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 3 is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R x is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R 4 is hydrogen; and

R 5 is hydrogen.

9. The method of claim 6 , wherein

R 1 is linear C 2 -alkyl, substituted with one substituent that is a terminal —N(R 12 )(R 13 ), wherein R 12 and R 13 are each a —C 2 -alkyl-CO 2 R 17 , wherein R 17 is hydrogen or R 17 is absent;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 3 is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R x is —CH 2 CH 2 CO 2 R e , wherein R e is hydrogen, C 1 -C 6 -alkyl, or R e is absent;

R 4 is hydrogen; and

R 5 is hydrogen.

10. The method of claim 1 , wherein the imidazoline compound has formula (III),

wherein

R 1 , R 4 , and R 5 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle,

said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocycle each independently, at each occurrence, unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, —COR 6 , —CO 2 R 7 , —SO 3 R 8 , —PO 3 H 2 , —CON(R 9 )(R 10 ), and —N(R 12 )(R 13 );

R 2 is a radical derived from a fatty acid;

R 6 , R 7 , R 8 , R 9 , and R 10 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl;

R 12 and R 13 are each independently, at each occurrence, selected from hydrogen, alkyl, —COR 14 , —CO 2 R 15 , -alkyl-COR 16 , and -alkyl-CO 2 R 17 ; and

R 14 , R 15 , R 16 and R 17 are each independently, at each occurrence, selected from hydrogen, alkyl, and alkenyl.

11. The method of claim 10 , wherein

R 1 is unsubstituted C 2 -C 6 -alkyl;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 4 is hydrogen; and

R 5 is hydrogen.

12. The method of claim 10 , wherein

R 1 is linear C 2 -alkyl, substituted with one substituent that is a terminal —N(R 12 )(R 13 ), wherein R 12 is hydrogen and R 13 is —COR 14 , wherein R 14 is —C 17 H 35 , —C 17 H 33 , —C 17 H 31 ;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 4 is hydrogen; and

R 5 is hydrogen.

13. The method of claim 10 , wherein

R 1 is linear C 2 -alkyl, substituted with one substituent that is a terminal —N(R 12 )(R 13 ), wherein R 12 and R 13 are each a —C 2 -alkyl-CO 2 R 17 , wherein R 17 is hydrogen or R 17 is absent;

R 2 is —C 17 H 35 , —C 17 H 33 , or —C 17 H 31 ;

R 4 is hydrogen; and

R 5 is hydrogen.

14. The method of claim 1 , wherein the quaternary amine has the formula

[N + R 5a R 6a R 7a R 8a ][X]

wherein

R 5a , R 6a , R 7a , and R 8a are each independently selected from substituted or unsubstituted C 1 -C 18 -alkyl; and

X is Cl, Br or I.

15. The method of claim 14 , wherein

R 5a , R 6a , R 7a , and R 8a are each independently selected from the group consisting of unsubstituted C 1 -C 18 -alkyl, C 1 -C 18 -hydroxyalkyl, and benzyl.

16. The method of claim 1 , wherein the quaternary amine is selected from the group consisting of tetramethyl ammonium chloride, tetraethyl ammonium chloride, tetrapropyl ammonium chloride, tetrabutyl ammonium chloride, tetrahexyl ammonium chloride, tetraoctyl ammonium chloride, benzyltrimethyl ammonium chloride, benzyltriethyl ammonium chloride, phenyltrimethyl ammonium chloride, phenyltriethyl ammonium chloride, cetyl benzyldimethyl ammonium chloride, hexadecyl trimethyl ammonium chloride, dimethyl C 12 - 16 -alkyl benzyl ammonium chloride, monomethyl di-C 12 - 16 -alkyl benzyl quaternary ammonium chloride, benzyl triethanolamine quaternary ammonium chloride, benzyl dimethylaminoethanolamine quaternary ammonium chloride, cocoalkyl dimethyl benzyl ammonium chloride, and combinations thereof.

17. The method of claim 1 , wherein the phosphonium compound is selected from the group consisting of alkyltris(hydroxyorgano)phosphonium salts, alkenyltri s(hydroxyorgano)phosphonium salts, tetrakis(hydroxyorgano)phosphonium salts, and combinations thereof.

18. The method of claim 17 , wherein the phosphonium compound is selected from the group consisting of C 1 -C 3 -alkyltris(hydroxymethyl)phosphonium salts, C 2 -C 3 -alkenyltris(hydroxymethyl)phosphonium salts, tetrakis(hydroxymethyl)phosphonium salts, and combinations thereof.

19. The method of claim 18 , wherein the phosphonium compound is selected from the group consisting of tetrakis(hydroxymethyl)phosphonium sulphate (THPS), tetrakis(hydroxymethyl)phosphonium chloride, tetrakis(hydroxymethyl)phosphonium phosphate, tetrakis(hydroxymethyl)phosphonium formate, tetrakis(hydroxymethyl)phosphonium acetate, tetrakis(hydroxymethyl)phosphonium oxalate, and combinations thereof.

20. The method of claim 1 , further comprising a demulsifier, and the demulsifier is selected from the group consisting of dodecylbenzylsulfonic acid (DDBSA), the sodium salt of xylenesulfonic acid (NAXSA), epoxylated and propoxylated compounds, anionic cationic and nonionic surfactants, and resins, phenolic and epoxide resins, and combinations thereof.

Assignments (6)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jul 17, 2025
From: JPMORGAN CHASE BANK, N.A.
To: CHAMPIONX LLC; APERGY ESP SYSTEMS, LLC; APERGY BMCS ACQUISITION CORP; HARBISON-FISCHER, INC.; NORRIS RODS, INC.,; NORRIS RODS, INC.,; NORRISEAL-WELLMARK, INC.; PCS FERGUSON, INC.; QUARTZDYNE, INC.; US SYNTHETIC CORPORATION
Reel/Frame 072004/0019 →
RELEASE OF SECURITY INTEREST Recorded Jun 7, 2022
From: BANK OF AMERICA, N.A.
To: CHAMPIONX USA INC.
Reel/Frame 060304/0267 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2020
From: ECOLAB USA INC.
To: CHAMPIONX USA INC.
Reel/Frame 053849/0537 →
SECURITY INTEREST Recorded Jun 5, 2020
From: CHAMPIONX USA INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 052848/0368 →
SECURITY INTEREST Recorded Jun 5, 2020
From: CHAMPIONX USA INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 053250/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2016
From: KEASLER, VICTOR; CLARK, JEFFREY CALEB; KELLER-SCHULTZ, CARRIE; BENNETT, BRIAN
To: ECOLAB USA INC.
Reel/Frame 039128/0672 →
Continuity (3)
Continuation 14448196 · Jul 31, 2014
Provisional Application 61861803 · Aug 2, 2013
Related Publication 20160374346A1 · Dec 29, 2016